Messenger RNA vaccines against SARS-CoV-2.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33740443.
- Also identified by DOI 10.1016/j.cell.2020.12.039 and PMC identifier 7805392.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3-4 weeks apart. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- COVID-19
- COVID-19 Vaccines
- SARS-CoV-2
- Vaccines, Synthetic